Carmen Barnes

Carmen Barnes has extensive work experience in the field of scientific research and pharmaceuticals. Carmen currently holds the position of Sr. Director of Liver Therapies at Homology Medicines, Inc., a role they have held since July 2020. Prior to this, they held the position of Director of Liver Therapies at the same company from June 2018 to July 2020. From March 2017 to June 2018, they worked as an Associate Director of Molecular and Cell Biology at the same company.

Before joining Homology Medicines, Inc., Carmen Barnes had worked at Celgene as a Principal Scientist from November 2014 to February 2017, and as a Senior Scientist from May 2012 to November 2014. Prior to their time at Celgene, they held the position of Senior Scientist at Alnylam Pharmaceuticals from 2009 to 2012.

Carmen Barnes began their career at Boston Children's Hospital, where they worked as an Instructor in Surgery from 1999 to 2009. During their time there, they focused on research projects related to angiogenesis-related diseases of pregnancy and infancy, including studies on omega-3 fatty acids for treating neuroblastoma and longitudinal clinical studies of 2-methoxyestradiol. Carmen also played a pivotal role in the development of antibodies for 2-methoxyestradiol and RGD-targeted platinum(IV) therapies.

Overall, Carmen Barnes has gained extensive experience in scientific research and has held various leadership roles in the field of pharmaceuticals.

Carmen Barnes obtained a Bachelor of Science (B.S.) degree in Chemistry from the Massachusetts Institute of Technology, where they completed their studies between 1990 and 1994. After that, they pursued a Ph.D. in Chemistry at the University of California, Berkeley, from 1994 to 1999.